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The Bcl-2 family of apoptotic regulators is thought to play an essential role in cancer development and influence the sensitivity of
tumour cells to radiotherapy. Bid is an abundantly expressed Bcl-2 family protein playing a central role in various pathways of
apoptosis by integrating and converging signals at the mitochondria. The relevance of apoptotic modulation by Bcl-2 and related
proteins in tumour development and radiation response for human tumours remains undefined. Therefore, a study was made
regarding the expression of Bid in patients with locally advanced cervix carcinoma who received radiotherapy. Bid expression was
assessed using immunohistochemistry in pretreatment archival biopsies from 98 patients. The data were correlated with
clinicopathologic characteristics and treatment outcome. Pretreatment tumour radiosensitivity data were available for 60 patients.
Strong Bid expression was associated with a patient age less than the median of 52 years (P¼0.034) and poor metastasis-free
survival. In multivariate analysis, after allowing for stage, Bid expression was a significant prognostic factor for both disease-specific and
metastasis-free survival (P¼0.026). It is concluded that strong tumour Bid expression is associated with poor outcome following
radiotherapy regardless of intrinsic tumour cell radiosensitivity, and is adverse prognostic for disease-specific and metastasis-free
survival in younger patients.
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Radiotherapy is the main treatment modality for locally advanced
carcinoma of the cervix. In spite of the reduction in incidence and
mortality in Europe and the USA, this disease remains one of the
major causes of female cancer-related deaths worldwide. Defective
apoptotic mechanisms may contribute to both malignant progres-
sion and radiation resistance of this tumour (Thompson, 1995;
Haimovitz-Friedman et al, 1996). The Bcl-2 family of apoptotic
regulators is believed to play an essential role in cancer
development and also to influence the sensitivity of tumour cells
to chemo- and radiotherapy. However, the relevance of apoptotic
modulation by Bcl-2 and related proteins in tumour development
and radiation response for human tumours remains undefined
(Brown and Wouters, 1999; Belka and Budach, 2002; Coultas and
Strasser, 2003).
Members of the Bcl-2 family include proapoptotic proteins such
as Bid, Bak, Bax and Bad, and antiapoptotic proteins such as Bcl-2
and Bcl-XL. They are related by homology domains, known as BH
domains 1–4, which are crucial for protein function and the
intermolecular association of family members. Apoptotic signals,
from intrinsic or extrinsic stimuli, are regulated via the relative
actions and interactions of prosurvival and prodeath Bcl-2
proteins (Chao and Korsmeyer, 1998, Kelekar and Thompson,
1998; Korsmeyer, 1999). The signals lead to the release of
apoptogenic factors (such as cytochrome C from mitochondria),
proteolytic caspase cascade activation and ultimately cell death
(Gross et al, 1999; Strasser et al, 2000; Cory and Adams, 2002).
Bid is an abundantly expressed BH-3 domain only protein that
plays a central role in various pathways of apoptosis by integrating
and converging signals at the mitochondria (Wang et al, 1996;
Footz et al, 1998; Li et al, 1998; Luo et al, 1998; Strasser et al, 2000;
Cory and Adams, 2002; Krajewska et al, 2002; Parone et al, 2002;
van Loo et al, 2002). Bid is known to bind and antagonise Bax and
Bak, at least one of which is absolutely required for the release of
mitochondrial apoptogens, and induces apoptosis by coupling the
proapoptotic activities of these proteins to the mitochondrial
surface (Li et al, 1998; Luo et al, 1998; Desagher et al, 1999;
Korsmeyer et al, 2000; Eskes et al, 2000; Wei et al, 2000, 2001;
Received 22 October 2004; revised 22 November 2004; accepted 23
November 2004; published online 1 February 2005
*Correspondence: Professor IJ Stratford; E-mail: ian.stratford@man.ac.uk
British Journal of Cancer (2005) 92, 449–458
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sCheng et al, 2001; Zong et al, 2001; Degli-Esposti, 2002). The best
characterised signalling activity of Bid takes place following death
receptor activation. Stimulation of death receptors such as Fas,
TNFR and TRAIL by their respective ligands results in Bid
activation in many cell systems (Li et al, 1998; Luo et al, 1998;
Yamada et al, 1999; Degli-Esposti, 2002; Tafani et al, 2002). In
response, caspase 8 is activated and subsequently cleaves Bid to
form truncated Bid (tBid). Truncated Bid is considered to be the
active form of the molecule that relocates to the mitochondria and
promotes the release of apoptogenic factors ( Li et al, 1998; Luo
et al, 1998; Gross et al, 1999; Wei et al, 2000; Degli-Esposti, 2002),
although full-length Bid can also induce apoptosis (Tafani et al,
2002; Sarig et al, 2003). Activation of Bid may also occur
independently of death ligand stimulation, such as in the cytotoxic
action of certain chemotherapeutic agents, or following activation
of caspase 8 in response to intrinsic apoptotic stimuli (Sun et al,
1999; Tang et al, 2000; Sax et al, 2002). Bid is also directly cleaved
by granzyme B, a protease delivered into target cells by cytotoxic T
cells and natural killer cells as an immune-surveillance response
(Barry et al, 2000; Heibein et al, 2000; Sutton et al, 2000). Thus, Bid
has a central role among the Bcl-2 family members. It connects the
intrinsic and extrinsic pathways for apoptosis, acts agonistically
upon other pro-apoptotic Bcl-2 proteins, and plays an important
role in apoptosis mediated by immune-surveillance mechanisms.
The aims of the present study were to investigate the expression
of Bid in archived pretreatment biopsies of cervix squamous cell
carcinoma, and to examine the results in relation to inherent
tumour radiosensitivity as measured by SF2 (West et al, 1993,
1997), tumour pathological characteristics and clinical outcome
following treatment with radiotherapy.
MATERIALS AND METHODS
Patients
Patients had histologically proven locally advanced squamous cell
carcinoma of the cervix (FIGO stage Ib–IVa) and were registered
at the Department of Oncology, Christie Hospital between 1987
and 1993. They were a consecutive series who received radiation
therapy with curative intent and for whom a biopsy was taken for
research. Patients were treated according to previous standard
techniques of the Manchester School as described elsewhere
(Pointon, 1991) before cisplatin was introduced as a concurrent
treatment. The South Manchester Ethical Committee granted
approval and prior informed consent was given by patients for
tumour biopsies to be taken for research purposes at the time of
their staging examination under anaesthesia. Clinical details of
patient age, disease stage and tumour grade are listed in Table 1.
Treatment outcome assessment was by review in specialist
oncology clinics, and from questionnaires sent to general
practitioners. The median followup time for surviving patients
was 60 months (range 17–101 months). Sites of disease relapse
were identified clinically and radiologically, and where appropriate
confirmed on biopsy. Disease-specific survival is the time from
start of radiotherapy to death due to cancer. Recurrence-free
survival is the time from start of radiotherapy to cancer recurrence
within the radiation field, and metastasis-free survival is the time
to recurrence outside the radiation field.
For some of the patients included in the study, data were
available from previous published work on tumour radiosensitivity
(West et al, 1993, 1997). Radiosensitivity was measured on
pretreatment tumour biopsies using an in vitro clonogenic assay
to obtain surviving fraction at 2Gy radiation (SF2).
Immunohistochemical staining for Bid
After deparaffinisation of tumour sections, microwave antigen
retrieval was performed in 10mM citrate buffer (pH 6.0) and
endogenous peroxidase was blocked with 3% methanolic hydrogen
peroxide. A standard DAB-based immunostaining procedure
employing an avidin–biotin complex reagent (DAKO) was used
to detect Bid protein after application of specific goat anti-Bid
antibody (R&D Systems, UK) at 1mgml
 1 overnight at 41C.
Table 1 Summary of patient distribution according to Bid expression
Bid expression
Parameter n 1234 P value
Stage
I3 2 1 2 6 7 7
II 28 7 8 8 5 0.14
III 32 5 4 12 11
I V 6 1221
Differentiation
Well 18 8 3 5 2
Moderate 58 12 11 17 18 0.095
Poor 17 4 6 3 4
Unknown 5 1 0 4 0
Age (years)
p52 51 8 11 17 15
452 47 17 9 12 9 0.034
SF2
Low (radiosensitive) 31 9 6 10 6
High (radioresistant) 29 5 6 8 10 0.19
Wildtype MEFs Bid knockout MEFs
Figure 1 Photomicrographs of wildtype and Bid knockout mouse embryonic fibroblast (MEF) cell pellets demonstrating specific immunoreactivity.
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sSections prepared from cell pellets of wild-type and Bid knock-out
mouse embryonic fibroblasts (Yin et al, 1999) were used as
controls for antibody specificity (Figure 1). The negative controls
were goat IgG preimmune fraction (Alpha Diagnostic International
Inc.) also at 1mgml
 1, and PBS. Several control slides of
predetermined Bid stain intensity were included in each batch to
eliminate batch-to-batch variability. The presence of negative and
positively stained nontumour cell types with consistent stain
intensity within the cervical tissues served as further internal
controls for stain specificity and fidelity.
Assessment of Bid staining
Tumour sections were assessed for the extent and intensity of Bid
expression specifically within tumour cells without the observer’s
knowledge of clinical data. Necrotic areas, stroma and non-
neoplastic epithelial cells were ignored. For the majority of
tumours, 90–100% of the tumour cells were Bid positive. However,
intensity of Bid stain varied from biopsy to biopsy and within
tumour cells of individual biopsy sections. A comparative
semiquantitative scoring index recommended for immunohisto-
chemical biomarker validation was used to reflect the intensity of
staining of individual cells and the percentage of cells that stained
at different intensities (National Cancer Institute: Requirements
for Pharmacokinetic and Biomarker Methods Development http://
www3.cancer.gov/prevention/pio/biomarkers.pdf). Bid stain inten-
sity was weighted as either absent (0), very weak (1), weak (2),
moderate (3) or strong (4) and, for each biopsy section, the
estimated percentage of tumour cells (to the nearest 10%) that
expressed Bid at each intensity was assessed and multiplied by the
corresponding weighted intensity value. These values were added
to obtain a final score for each biopsy with a theoretical range of
0–400. The frequency distribution of the final scores was normal
and quartiles were used to categorise scores (I–IV) for statistical
×20 ×20 ×40
×20 ×20 ×40
×20 ×20 ×20
×40 ×20 ×20
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Figure 2 Photomicrographs of cervix carcinoma sections depicting Bid stain categories. I¼lightest staining (A–C); II¼weak staining (D–F);
III¼moderate staining (G–I); IV¼strongest staining (J–L). Macrophages (M), neutrophils (N), plasma cells (P), smooth muscle cells (SM) were
immunopositive: stromal cells (Str), red blood cells (RBC) and lymphocytes (L) were negative.
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spurposes. Examples from each of these categories are illustrated in
Figure 2.
Statistical analysis
The reproducibility and concordance of scores were tested by
Spearman’s rank correlation and Altmann–Bland plot, respec-
tively. The distribution of Bid score in relation to patient and
tumour characteristics was investigated using either the Mann–
Whitney U rank sum test or Kruskall–Wallis test to analyse the
variance, and correlations were performed using Spearmans rank
method. Survival analysis was performed by the Kaplan–Meier
method, and prognostic factors were assessed by log-rank analysis.
Univariate and bivariate analyses were made of disease-specific
survival, local recurrence-free survival and metastasis-free survi-
val. Bid expression, patient age, tumour stage, grade and SF2 were
used to stratify patients. A stepwise multivariate Cox regression
analysis was also performed to test the independence of putative
prognostic parameters within the data set. All tests were two-sided
and a significance level of Pp0.05 was used throughout. All
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Figure 3 Bid expression and patient outcome. Disease-specific, recurrence-free and metastasis-free survival in relation to Bid expression in 98 patients
with squamous cell carcinoma who underwent radiation therapy. Bid expression was categorised I–IV (A) and subsequently analysed with categories I–III
grouped separately from category IV (B).
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Inc., Chicago, IL, USA).
RESULTS
Immunohistochemical expression of Bid
Bid immunostaining demonstrated a granular, cytoplasmic pattern
consistent with the cytoplasmic/mitochondrial/intercellular mem-
brane association of Bid (Coultas and Strasser, 2003). Weak to
moderate Bid immunoreactivity was detected throughout the
normal residual stratified squamous epithelium of the biopsy
specimens. Strong immunoreactivity was found in macrophages,
moderately positive staining in neutrophils and plasma cells, and
weak staining in smooth muscle cells of the cervical stroma and
some vessel walls. Stromal cells, red blood cells and lymphocytes
did not stain. Consistent intensity of Bid stain was obtained for the
different normal cell types, whereas tumour cell Bid stain intensity
varied (Figure 2). These observations are in agreement with a
previous study of Bid expression in normal and malignant tissues
that used alternative antibodies to detect Bid protein (Krajewska
et al, 2002).
Inter- and intraobserver reproducibility of scoring system
Tumour sections were scored twice by the first observer (MG) and
ranged from 100 to 380. A significant correlation was obtained
between the two scores (r¼0.92, Po0.001) with an Altman–Bland
plot equation of y¼ 0.0029x 2.058 showing good concordance.
A significant correlation was obtained (r¼0.93, Po0.001) when a
series of 35 randomly selected tumour sections were scored by a
second observer (GH).
Distribution of patients according to Bid expression
Table 1 summarises the distribution of patients according to
tumour Bid expression and clinical parameters. There was a
significant difference in tumour Bid expression for patients
stratified by the median age of 52 years, with a higher expression
in younger women (P¼0.034). This finding was supported by a
weak but significant inverse correlation between patient age and
Bid expression (r¼0.27, P¼0.007). There was no relationship
between the level of Bid expression and disease stage, differentia-
tion status and tumour radiosensitivity (SF2).
Bid expression and radiotherapy outcome
Bid expression was examined in relation to disease-specific, local
recurrence-free and metastasis-free survival by Kaplan–Meier and
log-rank analysis. A preliminary analysis revealed a trend for a
worse survival for patients with strong Bid expression (category
IV; Figure 3). Subsequent analyses were carried out, stratifying
patients into two groups of low/moderate (categories I–III) and
high (category IV) expression. High Bid expression was associated
with a worse outcome following radiotherapy (Figure 3). In
univariate analysis, disease stage and SF2 were the strongest
prognostic factors for radiotherapy outcome (Table 2). Bivariate
analysis was carried out to investigate the prognostic significance
of Bid expression in patients stratified by median age (Figure 4),
and it was found that the level of Bid expression in tumours was
associated with a worse prognosis in younger patients. To further
examine the relationship between Bid expression and poor
prognosis following radiotherapy, patients were stratified accord-
ing to Bid expression and survival was analysed according to
tumour cell radiosensitivity, (SF2, Figure 5); in those patients with
low/moderate tumour Bid expression, SF2 retained prognostic
significance for disease-specific, recurrence-free and metastasis-
free survival. However, for those patients whose tumours showed
strong Bid expression, SF2 was not prognostic, with the outcome of
treatment of the radiosensitive tumours becoming worse. In
multivariate analysis, after allowing for stage, Bid expression was a
significant prognostic factor for both disease-specific and metas-
tasis-free survival, and had borderline significance for recurrence-
free survival (Table 3).
DISCUSSION
The relevance of the Bcl-2 apoptotic regulators as determinants for
tumour progression and radiotherapy response in human tumours
is unclear. Previous studies have been carried out on other Bcl-2
family members in different cancer types, but varied methodol-
ogies, investigational strategies and treatment protocols have
confounded interpretation and comparison. This is the first study
to investigate expression of Bid and its clinical significance for
radiotherapy outcome in cervix carcinoma. Interpretation of the
results is aided by the homogeneous radiation only treatment
received by the patients in this study (before concurrent
chemoradiotherapy was introduced) and the availability of
complete long-term followup survival data.
Bid expression was widespread in normal and neoplastic
epithelial cells of the cervix tissues, although heterogeneity was
observed within and between individual tumour biopsies. The
extent and intensity of Bid expression between tumour biopsies
was compared and found to range widely, indicating substantially
altered regulation of Bid protein levels within the carcinomas
examined. Tumour Bid expression was higher in younger patients,
and was related to a more aggressive tumour phenotype which was
more likely to metastasise, but was not related to intrinsic tumour
cell radiosensitivity. Notably, strong tumour Bid expression was
prognostic for poor outcome, particularly for younger patients,
and could provide additional outcome prediction information
given tumour stage.
Variable expression of Bid was previously found in several types
of human cancers other than cervix carcinoma, including neural
tumours, colorectal adenocarcinomas, ovarian and prostate
cancers (Krajewska et al, 2002). Regulation of Bid expression
occurs via transcriptional and translational mechanisms and may
directly reflect variable levels of apoptosis within the tumours.
Conversely, altered regulation of Bid could occur via mutation,
post-translational modification or aberrant sequestration. This
could affect the protein half-life and activity of Bid, allowing an
accumulation of Bid protein although its normal proapoptotic
activity may be inhibited. It is therefore unclear whether strong Bid
immunoreactivity and its association with an aggressive tumour
type and poor prognosis is reflective of tumours with a high
proliferative capacity and concurrent increased apoptotic levels, or
due to defective function of Bid and reduced apoptotic potential.
No correlations were found between the expression levels of Bid
and previously determined measures of either apoptosis or
proliferation to aid in this interpretation. For tumours within this
cohort, a previous study has shown an association of increased
Table 2 Univariate log-rank analysis of putative prognostic factors for
outcome following radiation therapy in cervix carcinoma
Parameter n
Disease-specific
survival
Recurrence-
free survival
Metastasis-
free survival
Stage 98 0.0001 0.068 0.0008
Differentiation 93 0.69 0.10 0.69
Age 98 0.87 0.70 0.24
SF2 60 0.0036 0.0093 0.0059
Bid expression 98 0.074 0.11 0.048
The P-values for each factor are given.
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sapoptosis linked to poor prognosis (Levine et al, 1995). The 5-year
survival rate and time to local recurrence was significantly reduced
for patients with a tumour apoptotic index above the median.
Apoptosis also showed a positive correlation with the mitotic
index, indicating that apoptosis may be a reflection of tumour
proliferation (Levine et al, 1995). Our finding that the tumour
expression of the proapoptotic Bid is an adverse prognostic feature
is consistent with this previous work. Other studies in cervical
neoplasia have shown a positive correlation between proliferation
and apoptosis (Isacson et al, 1996; Shoji et al, 1996; Tsang et al,
1999a,b), and an association between high apoptosis and poor
disease-free survival (Tsang et al, 1999a,b). Although, in one study
high apoptosis was associated with a good prognosis in early-stage
disease (Wheeler et al, 1995), we have shown previously that the
prognostic significance of apoptosis in cervix cancer is dependent
on the tumour histology (Sheridan et al, 1999).
The increased prevalence for strong Bid expression in younger
patients is indicative of a genetic influence underlying Bid
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Figure 4 Patient age and outcome in relation to Bid expression. Patients were stratified according to median age (p52 years and 452 years) and
grouped by Bid expression.
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soverexpression, as patients who develop cancer earlier are more
likely to be genetically predisposed. The prognostic significance
determined specifically for younger women provides further
indication that strong Bid expression is associated with the earlier
development of more aggressive tumours that may be influenced
genetically. Genetic factors which may lead to Bid overexpression
may include direct mutations to the Bid gene, which result in
enhanced half-life of Bid protein within cells. For example,
mutation of Bid’s ubiquitin acceptor sites results in a stabilised
protein that is resistant to degradation (Breitschopf et al, 2000),
and specific mutations within Bid BH-3 domain results in Bid
protein that is defective in cytochrome release (Luo et al, 1998)
and unable to interact with Bcl-2 or Bax (Wang et al, 1996).
Table 3 Cox multivariate forward stepwise regression analysis to assess
the independence and impact of variable factors on patient survival
Parameter
Disease-specific
survival
Recurrence-free
survival
Metastasis-free
survival
Stage o0.0005 — 0.10 — 0.003 —
Age 0.87 0.54 0.76 0.96 0.25 0.36
Grade 0.69 0.60 0.12 0.053 0.69 0.81
SF2 0.005 0.003 0.015 0.018 0.009 0.013
Bid Expression 0.077 0.046 0.12 0.079 0.053 0.026
P-values for each factor are given. The left-hand columns give the P-value for each
parameter derived from the multivariate analysis. The right-hand columns give P-
values for each parameter after allowing for stage.
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Figure 5 Bid expression and relationship with intrinsic tumour radiosensitivity (SF2) and treatment outcome. Patients (n¼60) were stratified according to
Bid expression and grouped according to intrinsic tumour radiosensitivity (SF2). (A) Low/Mod Bid (I–III); (B) Strong Bid (IV).
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sMutations of Bid that affect the activity of the protein have also
been reported in gastric tumours (Lee et al, 2004), and mutant Bid
proteins, that mimic apoptotic defects observed in cells, have been
exploited in in vitro studies (Wang et al, 1996; Kuwana et al, 2002;
Letai et al, 2002). Tumourigenic aberrations to the post-transla-
tional control of Bid, such as its phosphorylation, cleavage or
myristoylation, may affect its apoptotic potential (Desagher et al,
1999, 2001; Zha et al, 2000; Puthalakath and Strasser, 2002; Degli-
Esposti et al, 2003).
A typical regulation or aberrant expression of other Bcl-2 family
members may influence the level of Bid protein detectable within
the cell and/or its functional ability. For example, Bcl-2 is
commonly overexpressed in a variety of tumour types including
cervix carcinoma (Chung et al, 2002), and has been shown to bind
and sequester Bid to prevent its normal activity (Wang et al, 1996;
Zong et al, 2001). Bax, Bak and Bcl-XL (which also bind Bid) and
caspases 3 and 8 (that directly affect Bid function) have also been
reported to be differentially regulated in cervix carcinoma (Chung
et al, 2002; Mukherjee et al, 2001). For this reason, assessment of
the relative levels of proteins known to antagonise Bid could be
valuable for the biopsies studied here. Alternatively, expression of
Bid may be influenced by tumourigenic changes to cellular
transcription factors such as p53, a known regulator of Bid mRNA
transcription following overexpression and/or stabilisation of p53
after DNA damage (Sax et al, 2002). Interestingly, for a subset of
the carcinomas studied here, the level of Bid expression was found
to correlate weakly with p53 immunopositivity (n¼42, r¼0.32,
P¼0.041), indicating a link between expression of the two
proteins. Recently, Bid was shown to be negatively regulated by
the hypoxia-inducible transcription factor HIF-1 (Erler et al, 2004),
and, as cervix carcinoma tumours are known to have variable
hypoxic fractions (Nordsmark et al, 2001), it is possible that Bid
expression may be linked to HIF-1 activity within tumours.
Tumour cells with other compensatory defects in apoptotic
mechanisms may tolerate elevated levels of Bid and/or prevent the
normal proapoptotic function of Bid. Elevated expression of
apoptosis inhibitor proteins, such as XIAP, cIAP or survivin, might
also allow downstream accumulation of Bid (Krajewska et al,
2003). Viral proteins expressed by certain human papilloma virus
(HPV) types are aetiologically involved in the development of
cervical cancer (Bosch et al, 1995; Zur Hausen, 2000) and may
indirectly influence the expression or function of apoptotic
regulators such as Bid. HPV type 16 has been shown to inhibit
apoptotic signalling induced by death receptors (Aguilar-Lemarroy
et al, 2001; Filippova et al, 2002), suggesting a method by which
increased Bid protein levels may become dysregulated and
tolerated by cells if upstream signalling becomes redundant.
If indeed Bid proapoptotic function is compromised, an
attractive theory to explain increased metastatic potential may be
the increased ability of tumour cells with reduced Bid function to
avoid Fas/TNFR/Granzyme B-mediated apoptosis, induced by
immune cells circulating in the body, thus enabling malignant
cells to invade surrounding tissue early in tumour development.
Similarly, defective Bid function could reduce the overall apoptotic
potential in response to radiation and may partly explain increased
rates of tumour recurrence following radiotherapy.
In conclusion, altered regulation of Bid expression within
cervical carcinoma was shown and overexpression of Bid was an
adverse prognostic factor for radiotherapy outcome. The relation-
ship between strong Bid expression and poor outcome following
radiotherapy was unrelated to in vitro measurement of intrinsic
tumour cell radiosensitivity, but was associated with a more
metastatic and aggressively malignant tumour phenotype in
younger patients. Further study is required to examine the
mechanism of Bid overexpression and its subsequent impact on
apoptotic potential and disease phenotype. However, the results
link Bid apoptotic signalling to tumour progression and treatment
response, and may aid the development of tailored combined
treatment and disease monitoring schedules for individual
patients.
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